HANGZHOU, China, September 18, 2024, Aomo Pharma, Inc. (the US branch of Adamerck) announced today that the China National Medical Products Administration (NMPA) accepted its new drug application (...
2024-09-19
HANGZHOU, China, March 5, 2024-The18th World Congress of Anesthesiologists (WCA), organized by the World Federation of Societies of Anesthesiologists (WFSA), was held in Singapore from March 3rd to...
2024-03-07
HANGZHOU, China, January 31, 2023-The Phase I clinical trial of Aom0315, an innovative drug with a novel target, officially reached its Last Patient Last Visit (LPLV)in Australia.
2024-02-18
HANGZHOU, November, 20, 2023- World Health Organization announced that amogammadex was designated as the International Nonproprietary Name of adamgammadex (Aom0498) on November 20, 2023. The propos...
2024-01-12
HANGZHOU,China, November 22, 2023- AMCKAUS Pharm (Australia branch of Adamerck) completed dosing of single ascending dose phase I clinical trial of Aom0315 conducted in healthy subjects in Australi...
2024-01-12
HANGZHOU, China, November 28, 2023- Recently, British Journal of Anasthesia published the pivotal Phase III clinical results of adamgammadex.This phase III clinical study is a multicentre, randomis...
2024-01-12
|
|
US Address: 1608 E AYRE NEWPORT DE 19804, USA
Australia Address: 7 DERHAM ST SPOTSWOOD VIC 3015
Contact 1: 1-347-766-6808
Contact 2: 512-831-8217
E-mail:alobal@adammerck.cor
In-depth Look